Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06239194 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Head and Neck Cancer, sponsored by ModeX Therapeutics, An OPKO Health Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 6
- Study locations
NCT06239194 is a Phase 1 study of Breast Cancer and Head and Neck Cancer that is actively recruiting participants, run by ModeX Therapeutics, An OPKO Health Company. The registered enrollment target is 115 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06239194, a Phase 1 study of Breast Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by ModeX Therapeutics, An OPKO Health Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG MDX2001
Study Locations (6)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Colorado
- Sarah Cannon Research Institute - Denver
Florida
- Sylvester Comprehensive Cancer Center - University of Miami Health System - Miami
Massachusetts
- Massachusetts General Hospital - Boston
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06239194
The ClinicalTrials.gov registry entry for NCT06239194 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is ModeX Therapeutics, An OPKO Health Company, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MDX2001 is the first listed.
NCT06239194 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06239194 about?
NCT06239194 is a clinical study titled "Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors". This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
What is the current status of trial NCT06239194?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2024-06-12. Estimated completion is 2029-02.
What conditions does trial NCT06239194 study?
This clinical trial studies the following conditions: Breast Cancer, Head and Neck Cancer, Endometrial Cancer, Gastric Cancer, Cervical Cancer.
What interventions are being tested in trial NCT06239194?
The interventions under investigation include: MDX2001 (DRUG).
Who is sponsoring clinical trial NCT06239194?
This trial is sponsored by ModeX Therapeutics, An OPKO Health Company, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06239194 being conducted?
This trial has 6 study locations across Colorado, Florida, Massachusetts, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.